trabectedin + dexamethasone

Trabectedin + dexamethasone is a **combination regimen** used primarily in the treatment of advanced soft tissue sarcomas, especially leiomyosarcoma and liposarcoma. Trabectedin is a marine-derived antineoplastic agent that acts as an alkylating agent, binding to the minor groove of DNA, disrupting DNA transcription and repair, and inducing apoptosis. Dexamethasone, a synthetic glucocorticoid, is given as prophylaxis—typically 20 mg intravenously 30 minutes before trabectedin infusion—to reduce trabectedin-induced hepatotoxicity and myelosuppression, and to prevent severe nausea and vomiting. Dexamethasone premedication is **standard of care in all patients receiving trabectedin**. The combination does not alter the anticancer activity of trabectedin but is essential for improving its safety and tolerability profile[1][3][4][5].